On August 6, Delcath Systems (NASDAQ:DCTH) reported second-quarter results that showed the company selling more of its liver cancer treatment than ever, even as the cost of running the business climbed just as fast. The interventional oncology company posted total revenue of $29.1 million, up from $24.2 million a year earlier, and used the report to raise its full-year revenue guidance. The numbers tell two stories at once, and investors will need to decide which one matters more.
A Cancer Therapy Gaining Real Traction
Delcath’s growth is coming from HEPZATO KIT, its liver-directed chemotherapy delivery system for metastatic uveal melanoma, which generated $27.1 million in the quarter compared with $22.5 million a year earlier. CHEMOSAT, the European version of the device, added another $2.0 million, up from $1.7 million. HEPZATO procedure volume grew roughly 30% year over year, and the number of active treatment centers using the therapy reached 31, evidence that physician adoption is spreading rather than plateauing. Gross margin widened to 90% from 86%, a sign the business is scaling efficiently as more of each new dollar in HEPZATO sales flows through to the bottom line.
The company backed that momentum by raising its 2026 revenue guidance to a range of $104 million to $108 million, implying HEPZATO volume growth of at least 28% for the full year. It also finished the quarter with $95.9 million in cash and investments and no debt, giving it room to keep expanding without leaning on outside financing. Beyond the current melanoma indication, independent investigators presented retrospective data at ESMO Breast Cancer 2026 showing a 60% hepatic partial response rate in heavily pretreated patients with liver-dominant metastatic breast cancer, and Delcath dosed the first patient in a global Phase 2 trial testing HEPZATO alongside standard of care in that same population. Two additional investigator-led studies, combining HEPZATO with tebentafusp in uveal melanoma and with nivolumab and relatlimab in melanoma that has spread to the liver, were also presented at ASCO 2026.
Growth That Costs More To Chase
The expense side of the ledger grew even faster than revenue. Research and development spending rose to $10.4 million from $6.9 million, which the company attributed to increased clinical headcount and trial activity tied to its expanding pipeline. Selling, general and administrative expenses climbed to $13.4 million from $11.4 million as Delcath kept building out its commercial footprint. Those increases show up directly in profitability: non-GAAP adjusted EBITDA fell to $7.6 million from $9.8 million even though revenue rose nearly 20%, and cash provided by operations dropped to $5.7 million from $7.3 million.
Net income held flat at $2.7 million in both quarters, meaning a meaningfully larger business produced no more bottom-line profit than it did a year ago. For a company still proving out a multi-indication strategy across breast and colorectal cancer, that pattern of spending ahead of returns is likely to continue for several more quarters before it reverses.
Wall Street Still Hedging Its Bets
Hedge fund ownership of Delcath slipped from 23 funds to 22, a modest pullback rather than a wholesale exit. Short interest stands at 7.04% of the float, a level that suggests a genuine bear camp has staked out a position without the stock being a crowded short. Together, the two figures describe a market that is watching the story unfold rather than committing firmly to either side of it.
The Real Test Still Ahead
Delcath’s second quarter makes the case that HEPZATO adoption is real and still climbing, backed by guidance that assumes the trend holds through year-end. But the same quarter shows that turning procedure growth into expanding profit is not yet happening, with adjusted EBITDA and operating cash flow both moving in the wrong direction. For the growth story to convert into a stronger financial one, R&D and commercial spending will need to level off while volume keeps compounding.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center